Probiotic and immunotherapy before liver cancer surgery
Part of Cancer, Digestive system clinical trials.
This study tests whether taking a specific probiotic (Lactobacillus reuteri) before surgery, along with standard immunotherapy, helps treat liver cancer better. You would take the probiotic daily, then have immunotherapy, and later potentially surgery to remove the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You need a confirmed diagnosis of hepatocellular carcinoma (a type of liver cancer).
- You must be planning to have immunotherapy before surgery to remove the tumor.
- You should not have had prior systemic treatment (like chemotherapy or immunotherapy) for liver cancer.
- Your liver function should be good or moderately good (Child-Pugh grade A or B).
- You need to be able to eat on your own, and not have taken probiotics or antibiotics in the last 2 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of two immunotherapy drugs before surgery can lower the chance of liver cancer coming back in people who have high-risk features. It may help patients with early-stage liver cancer that can be removed surgically.
This study tests whether giving a combination of two drugs—tislelizumab (an immunotherapy that helps your immune system fight cancer) and lenvatinib (a targeted therapy that blocks tumor growth)—before surgery can improve outcomes for people with early-stage liver cancer (a single tumor 2-5 cm) when the surgery is likely to have a narrow margin. You would receive the drugs for a few weeks before your scheduled surgery, and then have the surgery as planned. This approach may help reduce the chance of the cancer coming back.
This trial tests whether giving an immunotherapy drug called QL1706 before surgery can help lower the risk of liver cancer coming back. It is for people with early-stage liver cancer that is at higher risk of returning, and the goal is to see if this approach is safe and effective.
This trial tests giving two immunotherapy drugs directly into the tumor before surgery for liver cancer. It aims to see if this approach can shrink the tumor and improve outcomes for patients who are candidates for surgery.
This trial tests whether changing the bacteria in your gut (with a probiotic) can help your current immunotherapy work better if your liver cancer has been growing. It's for people with advanced liver cancer who will continue their same immunotherapy despite the cancer progressing.
This trial tests giving chemotherapy directly into the liver artery (HAIC) combined with immunotherapy before surgery for liver cancer that can be removed but is too large or numerous for standard treatment. The goal is to shrink the tumor and improve surgery results.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.